Can Noonan syndrome cause Fetal Growth Restriction (FGR) in a fetus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Noonan Syndrome Cause Fetal Growth Restriction?

Yes, Noonan syndrome can cause fetal growth restriction, though it is not a typical or common presentation during fetal life, and growth failure is predominantly a postnatal phenomenon in this condition.

Growth Pattern in Noonan Syndrome

The growth disturbance in Noonan syndrome follows a characteristic temporal pattern that is important to understand:

  • Birth weight is typically normal in infants with Noonan syndrome, indicating that intrauterine growth is generally preserved 1, 2.
  • Growth failure is mainly postnatal in character, dominated by slow maturation and delayed puberty, with the postnatal early decline appearing to be an intrinsic part of the syndrome 3.
  • Adult heights average approximately -2 standard deviations below the mean, but this results from cumulative postnatal growth failure rather than fetal growth restriction 3.

Prenatal Manifestations When Present

While FGR is not the hallmark of Noonan syndrome, when prenatal abnormalities do occur, they typically manifest as:

  • Third-trimester findings including polyhydramnios, skin edema, hydrothorax, and cardiac malformations rather than growth restriction 1.
  • First and second-trimester ultrasounds are usually normal, with the diagnosis of Noonan syndrome typically suggested only during the third trimester or after birth 1.
  • Transient nuchal translucency or cystic hygroma may be seen in early gestation but often resolve spontaneously 1.

Differential Diagnosis Context

Noonan syndrome is listed among genetic and teratogenic conditions to be considered in the differential diagnosis of fetal alcohol spectrum disorders (FASD), which do present with growth restriction 4. However, this inclusion reflects overlapping dysmorphic features rather than FGR being a primary feature of Noonan syndrome itself.

When evaluating early-onset FGR, chromosomal abnormalities account for approximately 6.4% of cases, and genetic syndromes should be considered 5. However, Noonan syndrome would be an uncommon genetic cause of isolated FGR given its predominantly postnatal growth pattern 3, 6.

Clinical Implications

  • If a fetus presents with isolated FGR without structural abnormalities, Noonan syndrome would be a low-probability diagnosis 1, 3.
  • If a fetus presents with third-trimester polyhydramnios, cardiac defects (especially pulmonary stenosis), hydrothorax, or nuchal abnormalities, Noonan syndrome should be considered even if growth is normal 1.
  • Chromosomal microarray analysis should be offered when FGR is detected with fetal malformation or when unexplained isolated FGR is diagnosed at <32 weeks gestation 5.

Mechanism of Growth Delay

The growth failure in Noonan syndrome appears to result from partial growth hormone insensitivity at a post-receptor level and possible derangements in the RAS/MAPK signaling pathway, rather than from placental insufficiency that would cause fetal growth restriction 7.

References

Research

Noonan syndrome: a cryptic condition in early gestation.

American journal of medical genetics, 2000

Research

Noonan Syndrome Presenting with Stunted Growth: A Case Report.

Mymensingh medical journal : MMJ, 2022

Research

Growth in Noonan syndrome.

Hormone research, 2009

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Early-Onset Fetal Growth Restriction: Causes and Evaluation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Etiology and Treatment of Growth Delay in Noonan Syndrome.

Frontiers in endocrinology, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.